Navigation Links
Cypher Sirolimus-eluting Coronary Stent Had Similar Results to,Bypass Surgery in Long-Term Study of Patients With Multi-Vessel,Coronary Artery Disease

.3 percent, respectively. Three-year stent thrombosis comparisons with the BMS arm were not possible, as the ARTS I Study did not track stent thrombosis rates beyond 30 days.

The CYPHER(R) Stent does not have an approved indication in the United States for patients with multi-vessel disease.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at www.cypherstent.com.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
4. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
5. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
6. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
9. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
10. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
11. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
Post Your Comments:
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 ... appointments of Dr. Ashraf Hanna , M.D., Ph.D., ... its Board of Directors. Dr. Hanna is the Vice ... and Chief Financial Officer for the Genentech Foundation, while ... Global Head of Business Development and Licensing for Roche ...
(Date:9/18/2014)... 18, 2014 Relmada Therapeutics, Inc., (OTCQB: RLMD), ... of chronic pain, announced today that it has appointed ... of  Senior Director of Clinical Development. During ... established and led successful global clinical operations teams, in ... facilitate the clinical development of numerous therapeutics and diagnostics ...
(Date:9/18/2014)... new expert panel report, Improving Medicines for Children ... by the Council of Canadian Academies, addresses the importance ... year about half of Canada,s ... Much of this prescribing is done off-label (i.e. the ... risks. Children have historically been excluded in ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
(Date:9/18/2014)... One of the most capable and ... ShandsCair Flight Program’s new EC155 B1, will ... at the Air Medical Transport Conference (AMTC), Sept. 22-24, ... into service ShandsCair EC155 and the Vanderbilt University ... AMTC highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... THURSDAY, Sept. 18, 2014 (HealthDay News) -- Daily supplements ... protect against the development of age-related cataracts among men, ... suggested that one or both could help prevent cataracts. ... Women,s Hospital and Harvard Medical School in Boston, and ... of selenium and vitamin E. The trial was initially ...
(Date:9/18/2014)... UT (PRWEB) September 18, 2014 Thousands ... will be recognizing their shared fundraising impact on 127 ... Sept. 25. , The first-ever Dance Marathon Day will ... $20 million projected to be raised by college and ... CMN Hospital. Donations generated through Dance Marathon campus programs ...
(Date:9/18/2014)... A group of international scientists have developed a new ... here . , The Wildlife Conservation Society (WCS)-led ... Tropical Diseases , describes the use of fecal samples ... have been exposed to the virus. This represents a ... can potentially change the way Ebola virus is studied ...
(Date:9/18/2014)... the Ebola virus invoke scary scenarios of deadly epidemics, ... are still providing researchers with new insights on how ... published online Sept. 18, 2014, in the journal ... Medical School Singapore detail how the Yersinia pestis bacteria ... the lymph nodes and eventually ride into the lungs ...
Breaking Medicine News(10 mins):Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:New insights on an ancient plague could improve treatments for infections 2
... , PASO ROBLES, Calif., July 28 ... California, will make silicone micro-implants such as surgical drains, catheter ... not routine is the incredibly precise tolerances demanded of these ... achieving consistently precise results to within .001 inch is no ...
... , MAITLAND, Fla. , July 28 ... treatment for infants with plagiocephaly and other head shape abnormalities, opened ... The Center currently also has offices in the Baltimore and Dallas ... orthoses, also commonly referred to as a cranial helmets or headbands. ...
... HARBIN, China, July 28 /PRNewswire-Asia-FirstCall/ -- China ... Company") (Nasdaq: CSKI ), a,leading fully integrated ... China ("PRC"), today announced that the,Company is scheduled to ... in early August, 2009. , ...
... , VANCOUVER, July 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: ... "Company") today announced encouraging interim data from an ongoing ... the punctal plug delivery system. These studies are part ... QLT,s wholly-owned subsidiary, QLT Plug Delivery, Inc. , Preliminary ...
... , , THE WOODLANDS, Texas, ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough ... financial results for the three months and six months ended June 30, ... progress, including the recent initiation of a Phase 2 study of LX1032 ...
... MINNEAPOLIS, July 28 ATS Medical, Inc. (Nasdaq: ATSI ... that it will participate in two upcoming investor conferences. ... The Company will participate in the 9th Annual BMO ... in New York. Michael Kramer, CFO of ATS Medical, will ...
Cached Medicine News:Health News:When You Make Things That Get Implanted in People, Small Things Count 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 3Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 4Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 5Health News:China Sky One Medical, Inc. to Conduct Non-Deal Roadshow in Hong Kong and Singapore 2Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 2Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 3Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 4Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 5Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 6Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 7Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 2Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 3Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 4Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 5Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 6Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 7Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 8Health News:ATS Medical to Participate at Upcoming Investor Conferences 2
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... designed with the safety and comfort of the ... (also called SF-6) leaded glass, the industry standard ... as set for optical clarity, visible light transmission, ... is protecting your eyes, it also helps you ...
B-52 Wrap Frame...
Medicine Products: